MyBlueDotsBioSkryb Genomics Launches ResolveSEQ MRD: A Next-Generation Measurable Residual Disease (MRD) Discovery Solution MyBlueDots5 months ago01 mins DURHAM, N.C.–(BUSINESS WIRE)–BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells. Post navigation Previous: Instem Introduces Cloud-Hosted Non-GLP Pathology Module for ProvantisNext: RefleXion Launches Pivotal Study to Expand SCINTIX Therapy and Announces Broader Medicare Reimbursement
‘Master control switch’ protein that heightens neurodegenerative disease offers new treatment target MyBlueDots3 days ago 0
New findings reveal how the heart is organized from the earliest stages of embryonic development MyBlueDots3 days ago 0
Scholastic performance is a key concern for young cancer patients, study finds MyBlueDots3 days ago 0